不同病理特征下乳腺癌患者细胞免疫水平及血清糖类抗原153变化分析

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (30 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the changes of cellular immunity and serum carbohydrate antigen 153 (CA153) levels in breast cancer patients under different pathological characteristics. Methods A total of 104 patients with breast cancer admitted to Heze Municipal Hospital from January 2019 to May 2020 were retrospectively selected as the study subjects and set as the breast cancer group, seventy patients of benign breast disease admitted to Heze Municipal Hospital at the same period were selected as benign groups, and seventy patients with physical examination in Heze Municipal Hospital in the same period were selected as the healthy control group. The immune indicators (CD4, CD8,CD4/CD8, NK) and CA153 levels of the three groups were compared, and observed the relationship between different pathological characteristics and immune indicators and CA153. Results The levels of CD4, CD4/CD8, and NK in the breast cancer group were lower than those in the benign group and the healthy control group, and the differences were statistically significant (P＜0.05). The levels of CD8 and CA153 in the breast cancer group were higher than those in the benign group and the healthy control group, and the differences were statistically significant (P＜0.05). The levels of CD4, CD4/CD8, and NK in the benign group were lower than those in the healthy control group, and the differences were statistically significant (P＜0.05). The levels of CD8 and CA153 in the benign group were higher than those in healthy control group, and the differences were statistically significant (P＜0.05). The CD4, CD4/CD8 and NK levels were compared between the patients with different age, with or without lymph node metastasis, the differences were statistically significant (P＜0.05). The CD4, CD8, CD4, CD4/CD8, NK, and CA153 levels were compared between the patients with different pathological types, TNM stage, tumor diameter, PR, ER, and HER-2 expression, and the differences were statistically significant (P＜0.05). Conclusion The cellular immunity level and CA153 level of breast cancer patients are related to clinicopathological type, TNM stage, tumor diameter size, ER, PR, HER-2 expression, and can be used as effective indicators to distinguish breast cancer from benign breast diseases and healthy people.

Key words： Breast cancer Immune level Serum carbohydrate antigen 153 Pathological characteristics

Received: 23 August 2021

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I35/192

[1]	王心然，张宁宁，吕菲，等.乳腺癌原发灶与转移灶间质浸润免疫细胞PD-L1 的表达异质性分析[J].中华病理学杂志，2020，49（5）：430-434.
[3]	李帅，马文静，马晶，等.乳腺癌新辅助治疗病理完全缓解的影响因素及预后[J].中国当代医药，2019，26（5）：95-97.
[4]	龚玉芳，姜斌，刘峰.乳腺癌患者血清趋化因子配体8，白细胞介素1-β，s CD200 的表达水平及临床意义[J].中国妇幼保健，2019，34（5）：1147-1150.
[5]	唐金海，赵建华，龚建平，等.化疗对乳腺癌患者血清血管生成调节因子水平的影响[J].中华肿瘤杂志，2007，29（3）：210-214.
[2]	Chung HL，Leung JWT.Breast cancer recurrences in myocutaneous flap reconstruction-ScienceDirect[J].Radiol Case Rep，2021，16（1）：40-46.
[6]	朱文文，赵娜，刘北星.乳腺癌肺转移过程中Th1/Th2 型细胞因子的动态变化[J].微生物学杂志，2020，40（1）：58-63.
[7]	王文慧，温媛媛，陈豪.血清神经生长因子及细胞免疫水平在乳腺癌中的表达及其与临床病理特征的相关性[J].中国医药导报，2020，17（11）：88-92.
[8]	尹志辉，周志伟，刘继勇，等.乳腺癌患者组织多项组化标记物与血清 CA153，CA125，CEA，25-OH-D3 水平关联性分析模型建立及在预后判断的临床价值[J].现代检验医学杂志，2019，34（3）：47-50，54.
[9]	李红涛.中药扶正抗癌方联合化疗对乳腺癌患者肿瘤标志物及免疫功能的影响[J].辽宁中医杂志，2020，47（3）：131-133.
[10]	朱思渊，王伏生，路晓庆，等.淋巴细胞亚群与乳腺癌淋巴结转移及脉管癌栓的相关性研究[J].医学研究杂志，2020，49（9）：77-81.
[11]	陈榕，陈国平，汪家航，等.乳腺癌患者围手术期免疫指标的变化及其临床意义[J].中华肿瘤杂志，2019，41（11）：849-853.
[12]	张凌宇，高海鹰，张庆洪，等.羟考酮联合氟比洛芬酯对于乳腺癌术后患者的镇痛效果及应激、免疫水平的影响[J].中国医院药学杂志，2019，39（11）：1166-1170.
[13]	姚远.右美托咪定对乳腺癌根治术患者Th1/Th2 细胞因子及免疫功能的影响[J].海南医学院学报，2017，23（19）：2724-2727.
[14]	苏国新，朱小丽，苏雅萍，等.大株红景天注射液对晚期乳腺癌患者生活质量和免疫功能的影响[J].中国医药导报，2019，16（20）：133-136.
[15]	殷隽逸，王雅灵，胡海燕.VitD/VDR 与乳腺癌患者免疫状态,临床特征及预后的相关性研究[J].中国癌症杂志，2019，29（5）：372-378.
[16]	邢丹，司婧，陈彩萍.乳腺癌术后肺部感染危险因素及其外周血细胞因子的变化[J].中国现代医生，2020，58（30）：50-52，57.